Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

open access

Vol 13, No 4 (2009)
Editorial
Published online: 2009-07-21
View PDF (Polish) Download PDF file
Get Citation

Losartan, allopurinol - is there any evidence, that hyperuricemia may become the new therapeutic target in cardiovascular protection of patients with arterial hypertension?

Katarzyna Kostka-Jeziorny, Andrzej Tykarski
Nadciśnienie tętnicze 2009;13(4):219-238.

open access

Vol 13, No 4 (2009)
Artykuły redakcyjne
Published online: 2009-07-21

Abstract

The association of elevated serum uric acid with cardiovascular disease has been recognized for more than a century. Despite long-standing awareness of this association, little attention has been paid to its potential significance. Several pathophysiological mechanisms linking serum uric acid (SUA) to cardiovascular damage at the cellular and tissue level have been proposed, including proliferation of vascular smooth muscle cells, stimulation of the inflammatory pathway, and possible prothrombotic effects mediated by platelet activation. This paper reviews the potential mechanisms by which SUA might be causally related to cardiovascular disease in patients with hypertension. We critically appraise the evidence in favour of a causal, coincidental or compensatory relationship, and consider the potential outcomes of lowering SUA (by losartan or allopurinol) in patients with hypertension.

Abstract

The association of elevated serum uric acid with cardiovascular disease has been recognized for more than a century. Despite long-standing awareness of this association, little attention has been paid to its potential significance. Several pathophysiological mechanisms linking serum uric acid (SUA) to cardiovascular damage at the cellular and tissue level have been proposed, including proliferation of vascular smooth muscle cells, stimulation of the inflammatory pathway, and possible prothrombotic effects mediated by platelet activation. This paper reviews the potential mechanisms by which SUA might be causally related to cardiovascular disease in patients with hypertension. We critically appraise the evidence in favour of a causal, coincidental or compensatory relationship, and consider the potential outcomes of lowering SUA (by losartan or allopurinol) in patients with hypertension.

Full Text:

View PDF (Polish) Download PDF file
Get Citation

Keywords

hyperuricemia; uric acid; losartan; allopurinol; uricosuric agents

About this article
Title

Losartan, allopurinol - is there any evidence, that hyperuricemia may become the new therapeutic target in cardiovascular protection of patients with arterial hypertension?

Journal

Arterial Hypertension

Issue

Vol 13, No 4 (2009)

Article type

Editorial

Pages

219-238

Published online

2009-07-21

Page views

660

Article views/downloads

5078

Bibliographic record

Nadciśnienie tętnicze 2009;13(4):219-238.

Keywords

hyperuricemia
uric acid
losartan
allopurinol
uricosuric agents

Authors

Katarzyna Kostka-Jeziorny
Andrzej Tykarski

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl